Who We Are

The New Jersey Life Sciences Vendors Alliance (NJLSVA) is a coalition of businesses, individuals and academia who provide goods and services to New Jersey’s life sciences companies.

The NJLSVA was founded to educate suppliers on trends in industry procurement and public policy that affects the life sciences industry.

Choose NJ’s RFP Watch

Choose New Jersey’s RFP Watch provides up-to-date information on business opportunities throughout the Garden State at a cost that is affordable for all companies – with a place of business in New Jersey – large and small.

To learn more click here

Biotechnology Innovation Organization (BIO)

Opinion: BIO CEO Jim Greenwood on ‘Don’t Let Fear Trump Science – Vaccinate Your Child’

Jim Greenwood

Washington, DC, August 24, 2017Biotechnology Innovation Organization (BIO) President and CEO Jim Greenwood wrote the following op-ed that was published in The Philadelphia Inquirer on August 23:

The nice lady had sugar cubes. My classmates and I lined up, single file, at Richboro Elementary School more than half a century ago, waiting for our taste. For a kid, it was a serendipitous moment — our parents were actually ordering us to consume sweets to keep us healthy.

These were no ordinary sugar cubes, though. We were in line to take the new oral polio vaccine. Continue reading

Trump Signs FDA User Fee Agreement into Law; PhRMA and BIO Applaud the Move

Washington, DC, August 21, 2017 — President Donald J. Trump on Friday signed into law a funding package for the Food and Drug Administration (FDA) that also takes steps to lower drug prices.

The FDA Reauthorization Act (FDARA) of 2017 reauthorizes a program in which drug and medical device makers pay the FDA a fee for every new product application.  The agency uses those funds to hire more people and speed up approvals.

The user fee program must be reauthorized every five years. The current program expires at the end of September, and if it hadn’t been signed into law before then, the agency would have had to lay off workers. Continue reading

NJEDA: Ideal Location, Unique State Resources Give Enteris BioPharma Advantage in Global Marketplace

Trenton, NJ, June 25, 2017 — This week’s BIO International Convention gave leaders from New Jersey’s vast life sciences ecosystem the chance to show emerging companies the advantages of establishing themselves within the State, such as its ideal location on the Eastern seaboard and the large number of pharmaceutical giants that currently call the State “home.”

“The Garden State is truly the best place to start a biopharmaceutical company,” New Jersey Economic Development Authority (EDA) Chief Executive Officer (CEO) Melissa Orsen said. Continue reading

BIO International Convention 2017 Closes After Four ‘Breakthrough’ Days in San Diego; BIO 2018 Set for Boston

Washington, DC, June 23, 2017 — The 2017 BIO International Convention (BIO 2017), hosted by the Biotechnology Innovation Organization (BIO), closed yesterday after four days of immersive, compelling programming united under the theme of “Breakthrough.”

BIO 2017 drew 16,123 biotechnology industry leaders from 48 States, the District of Columbia, Puerto Rico and 73 countries to San Diego, the “genomics capital” of the world.

As the largest global biotechnology event, BIO 2017 provided attendees with unique perspectives on the immense opportunities and complex challenges ahead for the industry. Continue reading

Choose New Jersey Showcases State’s Assets, Resources at BIO International 2017 This Week

Princeton, NJ, June 22, 2017 — A delegation representing more than 20 New Jersey organizations, including top life sciences companies, universities, trade associations, State government and Choose New Jersey, Inc. is showcasing New Jersey’s assets and resources for biotechnology companies at the New Jersey Pavilion (Booth #1737) at BIO International 2017, June 19-22 (2017) in San Diego, California.

During the world’s largest biotechnology conference, members of the New Jersey delegation are holding business meetings with executives representing companies in North America, Europe and Asia interested in learning more about the benefits of a New Jersey location. Continue reading

HINJ to Serve as Lead Sponsor of Choose New Jersey’s Annual Reception at BIO International on June 19 in San Diego

New Brunswick, NJ, May 19, 2016 — The HealthCare Institute of New Jersey (HINJ) will serve, once again, as the lead sponsor of Choose New Jersey’s annual reception at BIO International Convention on Monday, June 19 from 5:00 to 7:00 p.m. at Top of the Hyatt at the Grand Hyatt San Diego.

Choose New Jersey will showcase top life sciences companies, universities, trade associations, the State government at its New Jersey Pavilion (Booth #1737) at BIO International 2017, which will be held from June 19 to 22 at the San Diego Convention Center. Continue reading

BIO Offers Video Explaining How Drug Costs Are Really Determined

Washington, DC, April 3, 2017 — Today, much of the public debate surrounding the cost of biopharmaceuticals is focused on the list price of an individual drug or treatment regimen.

However, the list price is not what a manufacturer generally makes on the drug, and it typically has little to do with what a patient has to pay for his or her medicine.

To help put this debate into context, the Biotechnology Innovation Organization (BIO) in October unveiled an educational video today designed to give patients, consumers, policy makers and journalists a better understanding of how prescription drug costs are really determined and where the pharmaceutical dollar actually goes. Continue reading

Biotechnology Innovation Organization Statement on President’s Budget Proposal

Washington, DC, March 20, 2017Biotechnology Innovation Organization (BIO) Senior Vice President for Communications Kenneth Lisaius issued the following statement on March 17 regarding President Donald J. Trump’s budget blueprint:

“While we are still reviewing today’s budget blueprint, we have initial concerns with the proposed reductions in the budgets for biomedical research, public health, and for agencies that play an important role in promoting innovations in agricultural, environmental, and human health.

“We are encouraged by other language in the budget blueprint that seeks to improve the regulatory environment for such innovations. Continue reading

BIO Produces Video Explaining How Drug Costs Are Really Determined

 

Washington, DC, February 11, 2017 — Today, much of the public debate surrounding the cost of biopharmaceuticals is focused on the list price of an individual drug or treatment regimen.

However, the list price is not what a manufacturer generally makes on the drug, and it typically has little to do with what a patient has to pay for his or her medicine.

To help put this debate into context, the Biotechnology Innovation Organization (BIO) is releasing a new educational video today designed to give patients, consumers, policy makers and journalists a better understanding of how prescription drug costs are really determined and where the pharmaceutical dollar actually goes. Continue reading

BIO Video Explains How Drug Costs Are Really Determined

BIO Logo New NameWashington, DC, January 8, 2017 — Today, much of the public debate surrounding the cost of biopharmaceuticals is focused on the list price of an individual drug or treatment regimen.

However, the list price is not what a manufacturer generally makes on the drug, and it typically has little to do with what a patient has to pay for his or her medicine.

To help put this debate into context, the Biotechnology Innovation Organization (BIO) is releasing a new educational video today designed to give patients, consumers, policy makers and journalists a better understanding of how prescription drug costs are really determined and where the pharmaceutical dollar actually goes. Continue reading